摘要
目的 探讨Fas配体 (fasligand ,FasL)基因在肾细胞癌中的表达及临床意义。 方法 应用逆转录 聚合酶链反应 (RT PCR)及免疫组织化学技术分别检测FasLmRNA及蛋白在 51例肾细胞癌中的表达。结果 51例肿瘤中 32例FasL基因阳性表达。其中Ⅰ、Ⅱ、Ⅲ级肿瘤中FasL的阳性表达率分别为 2 5.0 %、63.6%、88.2 % ;Ⅰ、Ⅱ、Ⅲ Ⅳ期肿瘤中FasL的阳性表达率分别为 31 .6%、76.2 %、90 .9%。FasL的阳性表达率在肿瘤病理分级及临床分期间差异具有显著性 (P <0 .0 5)。
Objective\ To investigate the expression of fas lighand (FasL) gene in renal cell carcinoma (RCC) and its clinical implication.Methods\ Expression of FasL?mRNA and protein was detected by RT PCR and immunohistochemistry in 51 cases of RCC respectively. Results\ FasL gene expression was detectable in 32 of 51 cases of RCC. The positive expression rate of FasL were 25.0%, 63.6%, 88.2% in grade Ⅰ,Ⅱ,Ⅲ of RCCs and 31.6%, 76.2%, 90.9% in stage Ⅰ,Ⅱ,Ⅲ Ⅳ of RCCs respectively. The positive expression rate of FasL gene were related to the tumor grade and clinical stage ( P <0.05). Conclusion\ FasL gene expression might play an important role in the malignant progression of RCC.\;
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2000年第3期215-216,共2页
Chinese Journal of Experimental Surgery
基金
河南医科大学博士科研基金资助项目 !(HYY970 5)
